PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDoxorubicin
Doxorubicin hydrochloride, Caelyx pegylated liposomal(doxorubicin)
Doxil, Doxorubicin, Myocet, Pegylated (doxorubicin) is a small molecule pharmaceutical. Doxorubicin was first approved as Doxorubicin hydrochloride on 1982-01-01. It is used to treat breast neoplasms, gastrointestinal neoplasms, hodgkin disease, lung neoplasms, and myeloid leukemia acute amongst others in the USA. It has been approved in Europe to treat breast neoplasms, kaposi sarcoma, multiple myeloma, and ovarian neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
Show 1 more
Trade Name
FDA
EMA
Doxil, Doxorubicin (discontinued: Adriamycin, Doxorubicin, Rubex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Doxorubicin hydrochloride
Tradename
Company
Number
Date
Products
DOXIL (LIPOSOMAL)BaxterN-050718 RX1995-11-17
2 products, RLD
DOXORUBICIN HYDROCHLORIDEPfizerN-050629 RX1987-12-23
2 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
adriamycinANDA2024-04-11
doxilNew Drug Application2026-03-10
doxorubicin hydrochlorideNew Drug Application2026-05-05
doxorubicin hydrochloride liposomeANDA2026-02-24
doxorubicin hydrochloride, liposomalunapproved drug for use in drug shortage2023-12-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myeloid leukemia acute—D015470C92.0
breast neoplasmsEFO_0003869D001943C50
ovarian neoplasmsEFO_0003893D010051C56
thyroid neoplasmsEFO_0003841D013964—
gastrointestinal neoplasms—D005770C26.9
lung neoplasms—D008175C34.90
neuroblastomaEFO_0000621D009447—
precursor cell lymphoblastic leukemia-lymphoma—D054198C91.0
urinary bladder neoplasms—D001749C67
osteosarcoma—D012516—
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01D: Cytotoxic antibiotics and related substances
— L01DB: Anthracyclines and related substances
— L01DB01: Doxorubicin
HCPCS
Code
Description
J9000
Injection, doxorubicin hydrochloride, 10 mg
Q2049
Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
Q2050
Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Clinical
Clinical Trials
3055 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501074362071991793
LymphomaD008223—C85.91073361271636556
SarcomaD012509——7013148523248
Large b-cell lymphoma diffuseD016403—C83.35416055410247
Ovarian neoplasmsD010051EFO_0003893C567410969116236
NeoplasmsD009369—C80105771718182
Non-hodgkin lymphomaD008228—C85.94310041611176
B-cell lymphomaD016393——521022956163
CarcinomaD002277—C80.0337434527158
Liver neoplasmsD008113EFO_1001513C22.0256242834152
Show 41 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD064726——249621—9138
Fallopian tube neoplasmsD005185——313326—178
Stomach neoplasmsD013274EFO_0003897C16103411—958
RecurrenceD012008——19319—657
NeuroblastomaD009447EFO_0000621—102216—351
OsteosarcomaD012516——132411—849
Neoplasm metastasisD009362EFO_0009708—17256—446
Endometrial neoplasmsD016889EFO_0004230—62020——44
AdenocarcinomaD000230——9249—340
Peritoneal neoplasmsD010534——11157—636
Show 142 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive hydatidiform moleD002820—D39.2213———15
Non-small-cell lung carcinomaD002289——511———13
SyndromeD013577——37———10
GlioblastomaD005909EFO_0000515—47———10
CholangiocarcinomaD018281—C22.146——210
Plasmablastic lymphomaD000069293—C83.366———10
HypersensitivityD006967EFO_0003785T78.4045——410
Adult t-cell leukemia-lymphomaD015459—C91.546———9
Urologic neoplasmsD014571—C64-C6846———8
Myelodysplastic syndromesD009190—D4664———8
Show 146 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic-myeloproliferative diseasesD054437——4————4
Appendiceal neoplasmsD001063EFO_0003880C18.12———24
CystadenocarcinomaD003536——3————3
Skin neoplasmsD012878EFO_0004198C441———12
Sezary syndromeD012751—C84.11———12
Pleural effusionD010996—J901———12
Pleural neoplasmsD010997——1———12
Brenner tumorD001948——2————2
Castration-resistant prostatic neoplasmsD064129——1————1
Primary myelofibrosisD055728—D47.41————1
Show 16 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318EFO_0000319I98————44
FatigueD005221—R53.83————22
Pseudomyxoma peritoneiD011553EFO_0007456—————22
InflammationD007249MP_0001845—————22
Taste disordersD013651——————11
DysgeusiaD004408—R43.2————11
AgeusiaD000370EFO_1001758—————11
Biliary tract neoplasmsD001661—C24.9————11
AtaxiaD001259—R27.0————11
Ataxia telangiectasiaD001260Orphanet_100G11.3————11
Show 43 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDoxorubicin
INNdoxorubicin
Description
Doxorubicin is a deoxy hexoside, an anthracycline, an anthracycline antibiotic, an aminoglycoside, a member of tetracenequinones, a member of p-quinones, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It has a role as an Escherichia coli metabolite. It is a conjugate base of a doxorubicin(1+). It derives from a hydride of a tetracene.
Classification
Small molecule
Drug classantineoplastic antibiotics (daunorubicin type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Identifiers
PDB—
CAS-ID23214-92-8
RxCUI—
ChEMBL IDCHEMBL53463
ChEBI ID28748
PubChem CID31703
DrugBankDB00997
UNII ID80168379AG (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Doxorubicin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 129,848 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adriamycin, Doxil, Doxorubicin hydrochloride, Doxorubicin hydrochloride liposome
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
115,178 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use